Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma	Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Gaucher disease, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Nutritional and Metabolic Diseases, brain disorder, central nervous system disorder, connective tissue neoplasm, epithelial neoplasm, hereditary disease, inborn errors of metabolism, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, osteosarcoma, primitive neuroectodermal tumor, sarcoma, sphingolipidosis	Recruiting	Phase 1	2026-03-27		NCT03721068

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Bellicum Pharmaceuticals	12
National Cancer Institute (NCI)	3015
UNC Lineberger Comprehensive Cancer Center	125
United States Department of Defense	319

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Emory - Winship Cancer Institute	Atlanta	United States	3
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill	Chapel Hill	United States	8